Sunday, March 06, 2022 2:44:29 PM
Kiwi
“they “don’t believe in preventative cardiology” according to Bhatt,
Please provide a link to that comment to verify “
It was a video call between Dr Bhatt and myself, nobody else, no witnesses. There is no link. I wish I had recorded it but I didn’t think of it at the time. We talked about a lot of topics. He said he was the one that got KP to do the MITIGATE trial because they had the data to make it happen quickly and inexpensively. I asked why they couldn’t just mine their existing data for V Pts and see if there was a lower incidence of COVID. He replied they don’t have many Pts on V so I asked why? He said “they don’t believe in preventative cardiology I GUESS”. I left out the last 2 words and I’m going from memory from last June. Later I asked “shouldn’t all the control subjects be on V anyway?” To which he replied:” I suppose that’s true, (paused) like I said, they don’t believe in preventative cardiology”. The clear impression I got from him was that he was not a fan of KP.
Kiwi - how many 100,000’s of secondary prevention Pts does KP care for in their systems? Why aren’t they calling/texting these Pts to come in and get V??? If they did there would be a noticeable spike in V Rx in California.
Prevention means money up front for possible benefits in the future. Businesses (private/nonprofit/government) tend to be too focused on containing costs THIS QUARTER to think 5 years down the road for preventing an MI. Decision makers have to be on budget this quarter to get their bonus this quarter. Saving money from the hospital MI treatment budget does result in the drug expenses budget get more funds to cover for the 5 years of V. Different department different budget
“they “don’t believe in preventative cardiology” according to Bhatt,
Please provide a link to that comment to verify “
It was a video call between Dr Bhatt and myself, nobody else, no witnesses. There is no link. I wish I had recorded it but I didn’t think of it at the time. We talked about a lot of topics. He said he was the one that got KP to do the MITIGATE trial because they had the data to make it happen quickly and inexpensively. I asked why they couldn’t just mine their existing data for V Pts and see if there was a lower incidence of COVID. He replied they don’t have many Pts on V so I asked why? He said “they don’t believe in preventative cardiology I GUESS”. I left out the last 2 words and I’m going from memory from last June. Later I asked “shouldn’t all the control subjects be on V anyway?” To which he replied:” I suppose that’s true, (paused) like I said, they don’t believe in preventative cardiology”. The clear impression I got from him was that he was not a fan of KP.
Kiwi - how many 100,000’s of secondary prevention Pts does KP care for in their systems? Why aren’t they calling/texting these Pts to come in and get V??? If they did there would be a noticeable spike in V Rx in California.
Prevention means money up front for possible benefits in the future. Businesses (private/nonprofit/government) tend to be too focused on containing costs THIS QUARTER to think 5 years down the road for preventing an MI. Decision makers have to be on budget this quarter to get their bonus this quarter. Saving money from the hospital MI treatment budget does result in the drug expenses budget get more funds to cover for the 5 years of V. Different department different budget
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
